Sunday, July 8, 2012

Exelixis seeks 'cabo' approval in thyroid cancer, but big target is prostate cancer

(San Francisco Business Times subscription required.)
Cabonzantinib, a cancer drug that potentially could target multiple forms of the deadly disease as well as tumor-related bone pain, was submitted last month for Food and Drug Administration approval for a form of thyroid cancer. The treatment, known as “cabo” for short, takes South San Francisco-based Exelixis the closest to selling a drug after 18 years and a cumulative deficit of $1.1 billion.

No comments:

Post a Comment